Search

Additional file 1: Figure A1. Monthly cohort definition for AMI, HF or Pneumonia Readmissions and Observation Stays (Pg.2). Figure A2. Hierarchy for multiple post-discharge care events (Pg. 2). Table A1. Cumulative numbers and percentages of final action inpatient claims uploaded to the IDR for all conditions with a discharge date in January 2013 and July 2013 (as of December 2014) (Pg.3). Figure A3: Modeling approach (Pg.3). Figure A4. Timing of calculating monthly outcomes (Pg.4). Table A2. Final model specification for prediction of number of admissions, readmission rate, and observation-stay rate in AMI cohort (Pg.4). Table A3: Specifications of the final real-time reporting models for Heart failure and pneumonia (Pg.6). Table A4: Results of look-back validation where we compare the rates estimated (for the months July 2016 through December 2016) in February 2017 using RTR models with the final rates later observed using data downloaded from the IDR in February 2018 for AMI, HF and Pneumonia (Pg.7). Figure A5. Prediction and look-back validation for heart failure admission, readmission and observation stays (July 2016–December 2016) (Pg.8). Figure A6. Prediction and look-back validation for pneumonia admission, readmission and observation stays (July 2016–December 2016 (Pg.9).

BACKGROUND Cardiac embolism is an important etiology of cerebrovascular ischaemic events (CIE). Echocardiography is routinely performed in patients with CIE despite guidelines recommending restriction of echocardiography to patients with clinically suspected cardioembolism. OBJECTIVE The aim of this study was to examine the therapeutic impact and prognostic role of echocardiographic findings in an unselected population suffering from CIE. METHODS Between November 2006 and November 2007 319 patients with CIE underwent evaluation by transthoracic echocardiography (TTE) and in addition by transesophageal echocardiography (TEE) if deemed mandatory (n = 49). The combined clinical end point included death or recurrent CIE occurring during a follow up period of 3 and 12 months respectively. RESULTS After 3 months of follow up the combined end point was noted in 30 (9) and after 12 months in 43 (13) patients. In multivariate analysis atrial fibrillation (AF) (HR 2.12 95 CI 1.38 3.25; P < 0.001) and coronary artery disease (CAD: HR 1.85 95 CI 1.21 2.81; P = 0.004) were predictors of events occurring during short term follow up. After 1 year of follow up AF (HR 1.67 95 CI 1.19 2.32; P = 0.003) and CAD (HR 1.5 95 CI 1.09 2.06; P = 0.01) were associated with the combined end point. Echocardiographic parameters assessed at study entry were not independently related to an adverse outcome. CONCLUSION Whereas AF and CAD appear to increase the risk of events after suffering from CIE echocardiographic findings were not independently associated with the combined end point of recurrent CIE or death.

n/a

athlete's heart remodeling☆ A.M. Bernheim ⁎, M. Zuber , B. Knechtle , A. Linka , A. Faeh-Gunz , G. De Pasquale , B. Seifert , M. Pfyffer , B. Naegeli , C.H. Attenhofer Jost e,1 a Department of Cardiology, Stadtspital Triemli, Zurich, Switzerland b Department of Cardiology, Kantonsspital Lucerne, Lucerne, Switzerland c Gesundheitszentrum, St. Gallen, Switzerland d Department of Cardiology, Kantonsspital Winterthur,Winterthur, Switzerland e Cardiovascular Center, Klinik Im Park, Zurich, Switzerland f Division of Biostatistics, ISPM, University of Zurich, Zurich, Switzerland